Olaf Maier

Dr. Olaf Maier

Institute of Cell Biology and Immunology, Stuttgart University, Allmandring 31, 70569 Stuttgart, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
RFRoman Fischer
Roman Fischer
OMOlaf Maier
Olaf Maier
Neuroinflammation and mitochondrial dysfunction are common features of chronic neurodegenerative diseases of the central nervous system. Both conditions can lead to increased oxidative stress by excessive release of harmful reactive oxygen and nitrogen species (ROS and RNS), which further promote neuronal damage and subsequent inflammation resulting in a feed-forward loop of neurodegeneration. The cytokine tumor necrosis factor (TNF), a master regulator of the immune system, plays an important role in the propagation of inflammation due to the activation and recruitment of immune cells via its receptor TNF receptor 1 (TNFR1). Moreover, TNFR1 can directly induce oxidative stress by the activation of ROS and RNS producing enzymes. Both TNF-induced oxidative stress and inflammation interact and cooperate to promote neurodegeneration. However, TNF plays a dual role in neurodegenerative disease, since stimulation via its second receptor, TNFR2, is neuroprotective and promotes tissue regeneration. Here we review the interrelation of oxidative stress and inflammation in the two major chronic neurodegenerative diseases, Alzheimer’s and Parkinson’s disease, and discuss the dual role of TNF in promoting neurodegeneration and tissue regeneration via its two receptors.

6 March 2015 in Antibodies
Verified
Journal Article
Open access
PDF file
RFRoman Fischer
Roman Fischer
RKRoland Kontermann
Roland Kontermann
OMOlaf Maier
Olaf Maier
Deregulation of the tumor necrosis factor (TNF) plays an important role in the initiation and perpetuation of chronic inflammation and has been implicated in the development of various autoimmune diseases. Accordingly, TNF-inhibitors are successfully used for the treatment of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. However, total inhibition of TNF can cause severe side effects such as an increased risk of inflammation and reactivation of tuberculosis. This is likely due to the different actions of the two TNF receptors. Whereas TNFR1 predominantly promotes inflammatory signaling pathways, TNFR2 mediates immune modulatory functions and promotes tissue homeostasis and regeneration. Therefore, the specific blockage of TNFR1 signaling, either by direct inhibition with TNFR1-selective antagonists or by targeting soluble TNF, which predominantly activates TNFR1, may prevent the detrimental effects associated with total TNF-inhibitors and constitute a next-generation approach to interfere with TNF.

23 September 2008 in Glia
Verified
Journal Article
Closed access
PDF file
OMOlaf Maier
Olaf Maier
JJJenny De Jonge
Jenny De Jonge
ANAnita Nomden
Anita Nomden
DHDick Hoekstra
Dick Hoekstra
WBWia Baron
Wia Baron

1 October 2013 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
OMOlaf Maier
Olaf Maier
RFRoman Fischer
Roman Fischer
CACristina Agresti
Cristina Agresti
KPKlaus Pfizenmaier
Klaus Pfizenmaier

1 October 2014 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
RFRoman Fischer
Roman Fischer
MDMaelle Duffey
Maelle Duffey
NPNathalie Peters
Nathalie Peters
OSOliver Seifert
Oliver Seifert
OMOlaf Maier
Olaf Maier
KPKlaus Pfizenmaier
Klaus Pfizenmaier